Ono Pharmaceutical Co. (OTCMKTS:OPHLF) Sees Significant Growth in Short Interest

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) saw a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 3,578,303 shares, a growth of 51.3% from the July 15th total of 2,365,389 shares. Approximately 0.8% of the company’s stock are short sold. Based on an average daily volume of 483 shares, the short-interest ratio is currently 7,408.5 days.

Analyst Ratings Changes

Separately, Zacks Research upgraded shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Strong Buy”.

Ono Pharmaceutical Stock Performance

Shares of OTCMKTS OPHLF opened at $14.71 on Wednesday. The stock has a market cap of $6.91 billion, a price-to-earnings ratio of 14.01 and a beta of 0.33. The business has a 50 day simple moving average of $14.39 and a 200 day simple moving average of $14.80. Ono Pharmaceutical has a 52 week low of $10.27 and a 52 week high of $18.67. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.56 and a current ratio of 3.02.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.